AB

AbbVie

Every trial this sponsor leads in the registry, and everything it has published.

1,934All trials
Recruiting100
Recruited97
Not yet recruiting11
By invitation4
Completed1,471
Stopped246
Other5

212 active · 11% of this sponsor’s registry footprint

Oncology86 trials
Immunology & Inflammation36 trials
Dermatology22 trials
Neurology14 trials
Ophthalmology11 trials
Psychiatry & Addiction7 trials
Metabolic/Endocrine/Nutrition3 trials
Gastroenterology & Hepatology2 trials

Not shown above: 15 Phase 1 healthy-volunteer trials and 8 trials whose condition matched no therapy area.

Trials by phase

Phase 1474
Phase 2480
Phase 3642
Phase 4193
Unphased145

Pipeline by phase · 71 drugs in active development

Phase 3 · 22 drugs

Upadacitinib18 trials · 6 recruitingest. Jan 2027
Telisotuzumab Adizutecan (ABBV-400)15 trials · 8 recruitingest. Dec 2026
Risankizumab13 trials · 6 recruitingest. Jan 2027
Etentamig (TNB-383B)12 trials · 5 recruitingest. Feb 2027
Lutikizumab7 trials · 3 recruitingest. Dec 2026
Atogepant5 trials · 3 recruitingest. Mar 2028
Surabgene Lomparvovec (RGX-314)5 trials · 2 recruitingest. Oct 2026
Ubrogepant4 trials · 2 recruitingest. Oct 2026

Phase 2 · 17 drugs

Livmoniplimab5 trials · 2 recruitingest. Feb 2027
ABBV-9324 trials · 2 recruitingest. Nov 2026
Mirvetuximab Soravtansine4 trials · 2 recruitingest. Nov 2026
ABBV-2953 trials · 2 recruitingest. Jan 2027
Pivekimab Sunirine (IMGN632)3 trials · 2 recruitingest. Apr 2028
AGN-1515862 trials · 2 recruitingest. Oct 2026
AGN-151607-DP2 trials · 2 recruitingest. Sept 2028
Emraclidine2 trials · 2 recruitingest. Mar 2027

Phase 1 · 28 drugs

ABBV-3192 trials · 1 recruitingest. Feb 2027
Giloralimab (ABBV-927)2 trialsest. Mar 2027
Surzetoclax (ABBV-453)2 trials · 1 recruitingest. Dec 2030
ABBV-1011 trialest. Mar 2031
ABBV-10421 trial · 1 recruiting
ABBV-14511 trial · 1 recruitingest. Apr 2027
ABBV-17581 trial · 1 recruitingest. Oct 2030
ABBV-2431 trial · 1 recruitingest. May 2027

Phase 4 · 4 drugs

Venetoclax8 trials · 3 recruitingest. Nov 2026
Ibrutinib1 trialest. May 2027
OnabotulinumtoxinA1 trialest. Jun 2027

Not counted above: 3 combination backbones (established drugs used alongside the assets).

Active trials only, code names and brands merged. 1,471 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 7 of 10 curated

Multiple myeloma (Oncology)16 trials · 6 recruiting · 5 drugs2.1% of landscape
Non-small cell lung cancer (Oncology)13 trials · 6 recruiting · 6 drugs0.9% of landscape
Ulcerative colitis (Gastroenterology & Hepatology)11 trials · 4 recruiting · 3 drugs6.5% of landscape
Atopic dermatitis (Dermatology)10 trials · 3 recruiting · 2 drugs5.7% of landscape
Breast cancer (Oncology)4 trials · 2 recruiting · 4 drugs0.1% of landscape
Alzheimer's disease (Neurology)1 trial · 1 recruiting · 1 drug0.3% of landscape
Obesity (Metabolic & Nutrition)1 trial · 1 recruiting · 1 drug0.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon